CTLA4 and Hodgkins lymphoma: PD-1/PD-L1 (programmed death receptor 1, programmed death receptor ligand 1) inhibitors play a notable clinical role in B-cell lymphoma, especially in HL.31 CTLA-4 (cytotoxic T-lymphocyte antigen number 4) inhibitor also demonstrates certain curative effects in patients with HL and AML.32 There’re lots of clinical trials of these drugs applied to different kinds of hematologic malignancies to overcome resistance and relapse.